Graph Therapeutics has secured $5 million in Series A funding led by Daphni, bringing their total raised to over $10 million including prior equity and non-dilutive grants. This capital will accelerate their internal precision medicine pipeline for inflammatory diseases and further develop their AI-driven platform. The company leverages perturbation modeling and multi-omics profiling on patient samples to identify novel therapeutic targets.